Skip to content

Released Aug 8, 2013, after the close

10-Q filed Aug 8, 2013, 39 days after period end · 0001144204-13-043990

Q2 2013 · 10-Q
Revenue$2.26M−91.3% vs Q2 2012−36.5% vs Q1 2013
Net Income-$6.84MN/M vs Q2 2012N/M vs Q1 2013
EPS Diluted-$0.07N/M vs Q2 2012N/M vs Q1 2013
Gross Profit$1,746,000−92.1%
Operating Income-$6,894,000N/M
Operating Cash Flowderived-$8,109,000N/M
Free Cash Flowderived-$8,808,000N/M
Margins · derived
Gross margin77.1%−7.0 pt vs Q2 2012
Operating margin-304.5%−341.3 pt vs Q2 2012
Net margin-302.0%−338.9 pt vs Q2 2012

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2013Q2 2012Q2 2011Q2 2010
Revenue$2.26M$26.11M$764.00K$1.14M
Net Income-$6.84M$9.64M-$13.69M-$10.04M
EPS Diluted-$0.07$0.10-$0.16$0.12

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR